MOG-antibody associated disease

Romain Marignier MD, Yael Hacohen MD, Alvaro Cobó-Calvo MD, Anne-Katrin Pröbstel MD, Orhan Aktas MD, Harry Alexopoulos DPhil, Maria-Pia Amato MD, Nasrin Asgari MD, Brenda Banwell MD, Jeffrey Bennett MD, Fabienne Brilot PhD, Marco Capobianco MD, Tanuja Chitnis MD, Olga Ciccarelli MD, Kumaran Deiva MD, Jérôme De Séze MD, Kazuo Fujihara MD, Anu Jacob MD, Ho Jin Kim MD, Ingo Kleiter MD, Hans Lassmann PhD, Maria-Isabel Leite MD, Christopher Lintoning PhD, Edgar Meindl MD, Jacqueline Palace MD, Friedemann Paul MD, Axel Petzold MD, Sean Pittcock MD, Markus Reindl PhD, Douglas Kazutoshi Sato MD, Krzysztof Selmaj MD, Aksel Siva MD, Bruno Stankoff MD, Mar Tintore MD3, Anthony Traboulsee MD, Patrick Waters PhD, Emmanuelle Waubant MD, Brian Weisshenker MD, Tobias Derfuss MD, Sandra Vukusic MD, Bernhard Hemmer MD

Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France (R Marignier MD, S Vukusic, MD); Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, 69003 Lyon, France (R Marignier MD, S Vukusic, MD); Université Claude Bernard Lyon 1, F-69000 Lyon, France ((R Marignier MD, S Vukusic, MD)); Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK (Y Hacohen MD, O Ciccarelli MD); Centre d’Esclerosis Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d’Hebron. Universitat Autònoma de Barcelona. Barcelona, Spain (A Cobó-Calvo MD, M Tintore MD); Neurologic Clinic and Policlinic Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland (A-K Proebstel MD, T Derfuss MD); Medical Faculty, Department of Neurology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (O Aktas MD); Neuroimmunology Unit, Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece (H Alexopoulos DPhil); University of Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy (M-P Amato MD); Institute of Regional Health Research & Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark (N Asgari MD); Division of Child Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA (B Banwell MD); Department of Neurology and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (B Banwell MD); Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO USA (J Bennet MD); Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children’s Hospital at Westmead, Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (F Brilot MD); Regional Multiple Sclerosis Centre, Dept of Neurology, University Hospital S Luigi (Orbassano), Italy (M Capobianco MD); Department of Pediatric Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (T Chitnis MD); Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Hôpital Bisègre, Pediatric Neurology Department, National Referral Center for Rare Inflammatory Brain and Spinal Diseases, Université Paris-Sud, UMR 1184-CEA-IDMIT, Center for Immunology of Viral Infections and Autoimmune Diseases, 94275, Le Kremlin Bisègre, France (K Deiva MD); Department of Neurology, Strasbourg University Hospital and Clinical investigation center (CIC), INSERM 1434, Strasbourg, France (J De Séze MD); Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience for Neurology, Koriyama, Japan (K Fujihara MD); Division of Multiple Sclerosis and autoimmune neurology, Neurological Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates (A Jacob MD); Walton Centre NHS Trust, Liverpool, UK (A Jacob MD); Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea (Ho Jin Kim MD); Marianne-Strauß-Klinik, Behandlungszentrum Kempenhausen für Multiple Sklerose Kranken, Berg, Germany; Ruhr-University Bochum, Bochum, Germany (I Kleiter MD); Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna, Austria (H Lassmann PhD); Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK (M-J Leite MD, J Palace MD, P Waters PhD); Institute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow, G12 8TA, UK (C Lintingon PhD); Institute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig Maximilian University Munich, Germany (E Meindl MD); NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, and Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Berlin, Germany (P Paul MD); Moorfields Eye Hospital and National Hospital for Neurology and Neurosurgery, London, UK (A Petzold MD); University College London Queen Square Institute of Neurology, London, UK (A Petzold MD); National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London, UK (A Petzold MD); Department of Neurology, Mayo Clinic Rochester, MN, USA (S Pittcock MD); Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA (S Pittcock MD); Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA (S Pittcock MD); Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria (M Reindl PhD); Brain Institute of Rio Grande do Sul (BraIns) and School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil (D Kazutoshi Sato MD);
University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz, Poland (K Selmaj MD); Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Neurology, Istanbul, Turkey (A Siva MD); Sorbonne Université, Paris Brain Institute, ICM, CNRS, Inserm, and Saint Antoine Hospital, APHP, Paris, France (B Stankoff MD); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, Canada (A Traboulsee MD); Department of Neurology, University of California San Francisco (UCSF), San Francisco, CA, USA (E Waubant MD); Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA (B Weinshenker MD); Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany (B Hemmer MD).

Correspondence to:
Pr. Romain MARIGNIER – Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation – Hôpital Neurologique Pierre Wertheimer
59 boulevard Pinel – 69677 BRON cedex – France
E-mail: romain.marginier@chu-lyon.fr
Tel: +33 4 72 35 73 42 – Fax: +33 4 72 35 75 25

Word count: 3951 wwords
Abstract: 120 words
References: 106
Figures: 1
Tables: 2

Key-words: Myelin oligodendrocyte glycoprotein, optic neuritis, neuromyelitis optica, multiple sclerosis, MOG-antibody
MOGAD: review from the ECTRIMS workshop

Abstract

MOG-antibody-associated disease (MOGAD) is a recently identified autoimmune disorder presenting in both adults and children with central nervous system demyelination. Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis (MS), and aquaporin-4 antibody (AQP4-Ab) neuromyelitis optica spectrum disorder (NMOSD), cumulative biological, clinical and pathological evidence clearly discriminates between these conditions. Here we advocate that the diagnosis of MS or NMOSD should no longer be-used in the presence of MOG antibodies in the serum (MOG-Ab). Yet, many questions related to the clinical characterization and pathogenetic role of MOG-Ab are still open. Furthermore, current concepts on MOGAD therapy are mainly based on AQP4-Ab NMOSD and MS standard protocols, and more evidence is needed regarding who, how and when to treat MOGAD.
MOGAD: review from the ECTRIMS workshop

Introduction

Myelin oligodendrocyte glycoprotein (MOG) constitutes a quantitatively minor component (0.05%) of the central nervous system (CNS) myelin \(^1\) and is expressed on the outer lamella of the myelin sheath\(^1,2\). Though MOG knock-out mice display normal myelin ultrastructure and no apparent phenotype\(^3\), in human, MOG is thought to be involved in completion and maintenance of the myelin sheath and in cell-cell communication. While MOG has been controversially discussed as a putative autoantigen in autoimmune CNS demyelinating diseases for decades\(^4\), it is a well-established antigenic target in the experimental autoimmune encephalomyelitis (EAE) model\(^5,6\). Emergence of protein conformation-dependent assays\(^7\) for the detection of MOG-antibodies (MOG-Ab) has revealed a distinct clinical phenotypes in adults and children with CNS demyelination\(^8,9\). Different terms have been proposed to characterize patients with CNS syndromes associated with the presence of MOG-Ab. We will use here the term “MOG-Ab-associated disease” (MOGAD), which suggests the concept of an autonomous entity but does not preclude the incorporation of a heretofore unidentified clinical phenotype, and does not imply pathogenicity of the antibody itself.

Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis (MS), and aquaporin-4 antibody (AQP4-Ab) neuromyelitis optica spectrum disorder (NMOSD), cumulative biological, clinical and pathological evidence clearly discrimimates between these conditions. In patients with MOGAD the characteristics of lesion pathologies is characterized by inflammatory demyelination and not astrocytopathy as seen in AQP4-Ab disease. The perivascular deposits of activated complements and immunoglobulins which are typical for MS lesions are also rarely found. Furthermore, although MOGAD shares some overlapping pathological features with MS (such as demyelination and immune cell infiltration), the lesions in MOGAD are characterized by perivascular infiltrated MOG-laden macrophages, and CD4+ T cells infiltration by contrast to MS lesion which are characterized by CD8Tcells infiltration ,\(^10\).

Many questions, related to the clinical characterization and the pathogenetic role of MOG-Ab, are still open, and more evidence is needed regarding who, how and when to treat MOGAD. This review is based on a Focused Workshop on MOGAD, organized by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
MOGAD: review from the ECTRIMS workshop

The purpose of this Personal View paper was to review and discuss the immunology and pathology, the clinical spectrum and the current knowledge on treatment of MOGAD, from a large panel of expert in the field.

Search strategy and selection criteria

The review was composed from the 2-day ECTRIMS workshop and included topics and references discussed in the meetings. These topics were selected as key priorities in the field of MOGAD. Additionally, we searched PubMed for articles published in English between Jan 1, 1975, and March 1, 2021, using the search terms “myelin oligodendrocyte glycoprotein”, “neuromyelitis optica spectrum disorders”, “acute disseminated encephalomyelitis”, “optic neuritis”, “transverse myelitis”, OR “demyelinating diseases” combined with “MOG” OR “autoantibodies”. We prioritised articles published between 2016 and 2021, which correspond to the broadly use of recombinant antigens expressed on cells (cell-based assay, CBA) as the substrate for the MOG-IgG testing. We only included older material if it was seminal to the field. We excluded single case reports and data only published in abstract form and reviewed the bibliographies of included articles for additional references.

1. Clinical features in adults and children

MOGAD accounts for approximately 1.2-6.5% of all demyelinating syndromes in adults\textsuperscript{11, 12}. In children, the frequency of MOG-Ab seropositivity during a first acute demyelinating syndrome (ADS) is high, with multinational studies from Europe\textsuperscript{13-15}, North America\textsuperscript{16} and Australia\textsuperscript{17} identifying these antibodies in about 40% of all ADS presentations\textsuperscript{18}. The most common presentations, stratified to the different demyelinating phenotypes, are summarized in Table 1; for references see appendix pp 3–5).

In both adult and children the frequency is phenotype dependent. A single center retrospective study detected MOG-Ab in 12/20 (60%) of adults with ADEM either at onset or at follow-up\textsuperscript{19}. A Danish population-based prospective study detected MOG-Ab in 2/51 adults with a first ON\textsuperscript{20}, and the multicenter, randomized, placebo controlled Optic Neuritis Treatment Trial reported identified MOG-Ab in 3/177 (1.7%)\textsuperscript{21}. In AQP4-Ab seronegative longitudinally extensive transverse myelitis (LETM), two retrospective studies reported that 16-23% of individuals were MOG-Ab seropositive\textsuperscript{22, 23}. In children, MOG-Ab are identified most frequently in children with acute demyelinating encephalomyelitis (ADEM, up to 64\%\textsuperscript{24}) and in almost all those who relapsed following ADEM (multiphasic ADEM or ADEM-ON)\textsuperscript{25-28};
33-43% of children presenting with ON\textsuperscript{14, 16, 28}, but in only 6% (3/50) pediatric myelitis\textsuperscript{28}. MOG-Ab were identified in 26/110 (23.6%) children with relapsing demyelinating syndrome and 26/48 (54.2%) of non-MS relapsing demyelination\textsuperscript{9}. Most of the studies describing the frequency of MOG-Ab and the clinical phenotypes associated with it were performed in tertiary referral centers for neuroinflammatory disorders, which may lead to selection bias. This is especially relevant when evaluating clinical phenotypes such as optic neuritis (ON) or myelitis that might be referred only because of severe or atypical presentation. In addition, the first cohorts evaluated for MOG-Ab by CBA were restricted to patients with monophasic or recurrent ON or myelitis thus not reflecting the real frequency of MOG-Ab across all acute and chronic inflammatory demyelinating CNS diseases.\textsuperscript{29-32} Clinical phenotypes and paraclinical features stratified to the age of onset are summarized in Table 2.

No racial groups seem to be more or less likely to be diagnosed with MOGAD, by contrast to AQP4-Ab which is more common in non-Caucasians. There is an equal number of males and female in young children (<10y) and a slight female predominance (less so than in AQP4-Ab) in older post-pubertal children and adults\textsuperscript{33}. No definitive evidence has been reported linking MOGAD with other autoimmune diseases or specific malignancy. Although an HLA association, similar to other autoantibody associated disease is likely, in a recent study of 43 Dutch patients with MOGAD no significant HLA association was found\textsuperscript{34}. As found in other genetic and acquired white matter diseases, there is an age-dependent phenotype in MOGAD\textsuperscript{35}. Younger children are more likely to have brain involvement compared to older children and adults\textsuperscript{36, 37}. Similar to MS both the severity of the attacks and the recovery from attacks is also age-dependent, with with worse severity and better recovery in children\textsuperscript{38}. The risk of relapse is lower in children with the majority remaining monophasic\textsuperscript{16}. Less than 10% of children who relapse (typically very young children), can develop a leukodystrophy-like phenotype with large confluent highly enhancing lesions on MRI and significant brain atrophy over time \textsuperscript{35}. These children have poor outcome with permanent cognitive and motor disabilities\textsuperscript{35}. Younger children are more likely to have symptomatic brain involvement compared to older children and adults\textsuperscript{37}.

Recent cohort studies and case reports have shown that the disease course is very heterogeneous. The number of clinical relapses itself does not accurately explain the disability accrual at the individual level, possibly because of individual differences in the susceptibility for myelin damage and mechanisms of remyelination and repair. For instance, children under 9 years of age are more likely to have a severe brain pathology with higher lesion load detected on
MOGAD: review from the ECTRIMS workshop

conventional imaging than children older than 9 years of age\textsuperscript{37}; nevertheless, recovery from acute attacks appears faster than in older children and adults. This may not be disease specific and was also observed in comparison between adult and children with MS demonstrating that every 10 years of age, reduced EDSS recovery by 0.15 points\textsuperscript{39}. It is estimated that about 40\% of adult\textsuperscript{40,33} and 30\%\textsuperscript{18} of children\textsuperscript{28} with MOGAD present with a second clinical attack within five years.

Approximately 60\% of adult patients develop permanent neurological deficits, including motor and visual symptoms\textsuperscript{41} and about 50\% of children with relapsing MOGAD and brain involvement develop cognitive problems\textsuperscript{37}. Prediction of disability based on characteristics of the first attack remains elusive. Earlier studies suggested that high MOG-Ab titres could predict further clinical events\textsuperscript{15}, but more recent data indicate that patients may remain seropositive for many years and not relapse, and even patients who become seronegative may still relapse (and become seropositive at time of relapse)\textsuperscript{16}. Antibody titres, even when measured longitudinally, did not clearly correlate with disability outcomes\textsuperscript{8}. Similarly, baseline MRI parameters are not predictive of risk of relapse or disability\textsuperscript{16,33}.

2. Biomarkers

Assays for MOG-Ab detection

Over the last years, great efforts have been made to improve MOG-Ab detection techniques\textsuperscript{42}. More consistent results have occurred when the substrate for the tests were recombinant antigens expressed on live cells (live cell-based assay, CBA). As glycosylation and conformation of the protein play a key role in MOG-Ab recognition\textsuperscript{43-46}, surface expression of the full-length human MOG protein (usually α-1 isoform, 218 aminoacids) expressed typically on human embryonic kidney cells (HEK293)\textsuperscript{7} is used to detect pathogenic MOG-Ab more specifically. A summary of the immunopathology in MOGAD is illustrated in Figure 1 and panel 1. The frequency of MOG-Abs and their titers are higher during the acute attack among young children than among adolescents or adults\textsuperscript{32} but more likely to become negative after the attack\textsuperscript{16}. Timing of testing is important as antibody titers fluctuate and may decrease over months from presentation, and some can serorevert and being subsequently tested negative\textsuperscript{16}. A higher cut-off for seropositivity and use of specific secondary antibodies to IgG1 or IgG-Fcγ\textsuperscript{47} increased specificity (ranging from 99.6\% to 100\%)\textsuperscript{48}. The use of anti-IgG (H+L) secondary antibody is a matter of active debate. It was previously shown that using IgG (H+L) secondary antibodies may cross react with MOG-IgM which can be found in healthy controls\textsuperscript{47}. 
MOGAD: review from the ECTRIMS workshop

However, two recent studies demonstrated that IgG (H+L), IgG1 and IgG-Fcy antibodies were comparable, and no IgM binding was observed\textsuperscript{49,50}. These discrepancies are likely due to assay methodologies. Of note, the sensitivities and specificities reported in all these studies\textsuperscript{15, 16, 47-51} were evaluated in the research setting, and the applicability of this remains to be evaluated in the clinical context. Importantly, in a recent large multicenter comparative study MOG-Ab CBAs showed excellent agreement with each other for high positive and negative samples. Low positive/bordeline samples were more frequently discordant\textsuperscript{51}. These borderline/low MOG-Ab titers represent a currently undefined group and are likely to impact the sensitivity and specificity of the results across all MOG-Ab testing laboratories. Each credited laboratory uses specific cut off for positivity. Like with any test, low positive/borderline results are more frequently discordant and should be evaluated as such.

MOG-Ab are now rarely found in patients with typical MS using CBA. Only 0.4 % (1/244) MS patients were found MOG-Ab positive by live-CBA in a multicenter study\textsuperscript{52}. Accordingly, two cross-sectional studies reported detection of MOG-Ab in 0/200 patients with progressive MS\textsuperscript{53} and in 2/685 patients with relapsing or progressive MS from two tertiary centers\textsuperscript{11}. It is exceptionally rare for any patient to have serum antibody to MOG and AQP4\textsuperscript{8,42}. MOG-Ab-positive patients with clinical and paraclinical features discordant or uncommon for MOGAD must be closely monitored to determine the positive predictive value of this antibody for clinical management. This is particularly relevant in adult patients with MS, in whom testing of all patients with suspected demyelinating disease would result in many borderline results and probably false positives. With the current absence of established criteria for MOGAD, diagnosis in antibody-positive patients with atypical presentation, rests on the rigor of the test method and the expertise of the clinician.

One half of the patients presents with CSF pleocytosis (predominantly lymphocytes and monocytes) with cell numbers that often tend to be higher than in MS\textsuperscript{54,55}. Pleocytosis correlates with the extension of the disease being higher in ADEM or LETM phenotypes than in ON\textsuperscript{8}. Oligoclonal bands and a positive IgG index are found in less than 15%, mainly during attacks\textsuperscript{54,55}. The CSF cytokine profile during attacks in MOGAD seems to be more similar to AQP4-Ab NMOSD compared to MS\textsuperscript{56}. Finally, the usefulness of MOG-Ab detection in the CSF is not yet fully evaluated. When paired serum and CSF are analyzed, there is a good concordance between serostatus and CSF status; i.e. most CSF-positive patients are seropositive. Not all seropositive patients are CSF-positive, and only a small percentage are seronegative and CSF-positive\textsuperscript{57}. 
3. Imaging Biomarkers

Brain MRI in MOGAD can be abnormal in more than 50% of patients, regardless the clinical phenotype at presentation. In general, brain lesions are more widespread in children compared to adults reflecting a higher disease burden. Apart from the deep white and grey matter lesions found in ADEM-like phenotypes, brainstem lesions are found in up to 40%, frequently involving the pons and middle cerebellar peduncles. Interestingly, in a discriminant analysis using only routine clinical scans obtained on different MRI machines, MOG-Ab and AQP4-Ab related diseases could not be distinguished, but displayed different imaging characteristics from MS: lesions were poorly demarcated, fewer in number, and ‘Dawson fingers’ or lesions adjacent to the body of lateral ventricles were less frequent. Others have suggested that the involvement of cerebellum, brainstem or both as a part of a multifocal CNS episode is more likely to indicate the presence of MOG-Ab when compared with MS, but not with AQP4-positive patients. Dramatic lesion resolution on MRI, sometimes within a month of presentation, is not rare in MOGAD. Patients with MOGAD are less likely to develop clinically silent MRI lesions than patients with MS.

Although initially thought to be associated with predominantly white matter disease, both adults and children with MOGAD may experience cortical encephalitis and seizures. Brain MRI in these patients may be normal or may have reversible cortical changes occasionally with leptomeningeal enhancement. Recent reports of isolated seizures (with normal brain MRI) during the first episode of relapsing MOG-Ab associated demyelination in children and aseptic meningoencephalitis and pseudotumor cerebri-like presentations highlight that normal conventional imaging should not preclude the diagnosis and that contrast-enhanced scans can increase the diagnostic yield in symptomatic patients.

Spinal cord MRI findings, such as the presence of longitudinally extensive T2 lesions spanning at least 3 vertebral segments on sagittal sequences or the hyperintensity of the grey matter on axial sequences (longitudinally extensive transverse myelitis), may resemble those commonly seen in AQP4-Ab positive NMOSD. MRI features suggesting a diagnosis of MOG-Ab over AQP4-Ab or MS are involvement of the conus medullaris, abnormality confined to grey matter (sagittal line and axial H sign) and nerve roots, and lack of or minimal gadolinium enhancement. Occasionally, large lesions may be associated with mild impairment, a clinical-radiological paradox, particularly in children.
MOGAD: review from the ECTRIMS workshop

MRI of the optic nerves may demonstrate extensive T2-hyperintensity and T1-gadolinium enhancement that predominates in the anterior portion of the nerve. These features together with severe swelling of the optic nerve head with or without hemorrhage on fundoscopy can help differentiate MOGAD from episodes of ON in AQP4-Ab NMOSD and MS. A perineural edema is another radiological finding which is observed in up to half of MOGAD patients with optic neuritis.70-72

Optical coherence tomography (OCT): Patients usually display a thickening of the peripapillary retinal nerve fiber layer (pRNFL), likely due to the optic disk swelling at the acute phase of an ON attack.73 Subsequently, the pRNFL progressively evolves towards a progressive thinning which is greater in temporal quadrants. Although findings are still inconsistent, on average, optic neuritis associated with MOG-Ab causes less retinal damage than optic neuritis associated with AQP4-Ab.74 In affected eyes, longitudinal OCT analysis has found a decrease of the pRNFL but not of the combined ganglion cell and inner plexiform layer (GCIP) in the absence of new clinical attacks73, in contrast to the reduction of both layers observed in AQP4-ON and MS-ON over time.74, 75 In non-affected eyes, a subclinical neuroaxonal retinal damage has been found with a decrease of the GCIP. Conflicting results have been reported regarding the pRNFL involvement in this subgroup of patients73, 76 A subclinical chiasmal or optic nerve inflammation are the most likely explanation. Similarly to the MRI paradox, a clinical-radiological discordance has also been observed with OCT, with preserved visual acuity despite severe atrophy of RNFL77, in contrast to MS or AQP4-ON, in which RNFL thickness and visual acuity frequently correlate.78-80

4. Treatment

Attack treatment

There are currently no randomized control trial or evidence-based guidelines for the acute treatment of MOGAD relapses. There is no evidence that MOG-Ab positivity should influence acute attack treatment and most neurologists treat these patients according to the demyelinating phenotypes. Importantly, in most circumstances, MOG-Ab results are not available within the first few days of acute presentation, and thus do not guide immediate therapies.

Observational studies show that patients with MOGAD are highly sensitive to corticosteroids and may achieve complete and dramatic symptom remission following a short course of intravenous steroids.26, 33, 63, 81 First line immunotherapy therefore consists of intravenous
methylprednisolone (IVMP) (30mg/kg/ day or 1g; for 3-5 days). Treatment escalation is warranted for patients who do not improve following IVMP or individuals with a severe attack such as complete loss of vision, paralysis or severe encephalopathy requiring intensive care admission. In the absence of evidence directly related to MOGAD, the treatment algorithm proposed for CNS demyelination is followed in most expert centers, adapted to local clinical practice or age group. Escalation therapies include plasma exchange (PLEX, 5 exchanges on alternative days), immunoabsorption or intravenous immunoglobulins (IVIG, total of 2g/kg over 2 or 5 days), or PLEX followed by IVIG. As, it is the case in AQP4-Ab NMOSD, it may be anticipated that time to initiation of acute treatment is one of the predictors of long-term outcome.

The decision for how long and whether to wean the corticosteroids is a matter of active debate. The choice is dependent on the severity of the attack and the risk of flare-up while weaning the steroids too early. The decision of a prolonged oral steroid treatment probably depends also on timing and mode of action of the chosen relapse treatment and maintenance therapies. Classically, in adults, some centers proposed to use 1 mg/kg/day for 3 months and then progressively taper over the next 3 months. In a study of 59 patients with MOGAD, of the 146 episodes treated with oral prednisolone taper, the majority of the 103 subsequent episodes occurred towards the end of the taper or shortly after prednisone cessation. For children, the use of prolonged course of oral corticosteroids is also a matter of active debate. Some paediatricians apply a protocol similar to the one used for adults with 3-6 months oral steroids (akin to protocols used in rheumatological conditions); others feel strongly that the steroids course should be less than 4-weeks to avoid side effects and propose alternatively intravenous immunoglobulins for 3 to 6 months (expert opinion).

**Chronic treatment for relapse prevention**

The accumulation of disability in patients with antibody-mediated diseases, such as MOGAD, is thought to be primarily relapse-related. Given the risk of disability due to incomplete relapse recovery, identifying patients at risk for relapse, and treating those with relapses, is the main focus of current management. The clinical differentiation between true relapse, disease rebound (during steroid wean or shortly after discontinuation of steroids) or pseudo-relapses secondary to intercurrent illness is challenging. Clinical history and examination, preferably in specialist centers, are crucial when making treatment decisions.

Currently there are no predictors of risk of relapse and long-term outcome. Given that ~70% of pediatric patients will have a monophasic outcome, the decision to initiate chronic
MOGAD: review from the ECTRIMS workshop

Immunosuppression in a pediatric patient is even more controversial. Currently, with the absence of natural history studies and the known infectious risks of current immunosuppressive agents, most clinicians would start treatment only after a second event.

The decision regarding the need for a continuous immunotherapy for relapse prevention is typically influenced by (i) the response to treatment of initial attack; (ii) the severity of initial attack; (iii) risk of short-term disability (associated to the first episode or accumulation of episodes); (iv) risk of short- and long-term immunosuppression. ; and (v) age.

No clinical trials have been performed for patients with MOGAD and the current literature reports real-world clinical data which are not optimal for evaluation of treatment efficacy. Data from the six largest retrospective studies on treatment of relapsing MOGAD, revealed that at a median of 9-16 month, 20/29 (69%) of patients remained relapse free on IVIG monotherapy, 30/63 (47%) on mycophenolate mofetil, 21/55 (39%) on azathioprine and 47/94 (50%) on rituximab. Of note, although anti-CD20 therapy seems to show some effect, it appears less potent than in AQP4-Ab NMOSD. In AQP4-Ab NMOSD, relapses mostly occur when the biological effect of rituximab decreases, whereas in MOGAD patients may relapse despite absent B-cells. Importantly, time to treatment efficacy is highly variable, and need to be taken into account.

First-line injectable MS treatments (interferon-beta and glatiramer acetate) were shown to be ineffective in preventing relapses in both adults and children with relapsing MOGAD, with no change in annual relapse rate. Although conceptually the use of natalizumab may prevent autoreactive T-and B-cells from accessing the brain case reports of natalizumab use in patients with suspected MS but finally diagnosed with MOGAD, severe relapses were reported in 5 out of 6 patients. There are only anecdotal reports for alemtuzumab, dimethyl fumarate, and fingolimod, not allowing judgement of treatment efficacy.

5. Conclusions and future directions

The key to improving outcomes in MOGAD is (i) making early diagnosis based on accurate and reproducible detection of MOG-Ab (ii) improved understanding disease mechanisms leading to relapses and disability accumulation and (iii) establishing treatment protocols. There are currently no formal criteria for the diagnosis of MOGAD. Once established and validated, these will improve time to diagnosis and diagnostic accuracy.
MOGAD: review from the ECTRIMS workshop

A key question in view of the phenotypical heterogenicity seen with MOGAD, is whether patients with MOG-Ab presenting with NMO, ADEM or cortical encephalitis may in fact have different pathobiology driving their disease and should therefore be treated differently. To provide further evidence on the mechanisms involved in MOGAD, it is essential to improve our in vivo and in vitro models. Human-derived oligodendrocyte cultures, rodent models with humanized MOG or animal models with a higher homology to human MOG (e.g. rhesus monkeys) will provide a better basis to investigate the pathogenic mechanisms. The methodological challenge of measuring antigen specific CD4+ T and B cells, which are most likely present in the peripheral blood of MOGAD patients at low frequency, are major obstacles that will have to be overcome in order to address frequency and phenotype of these cells. These studies are important to better understand the mechanisms behind the development of an autoimmune response to MOG and may pave the way for antigen specific immune therapies.

With the rarity of the condition, multicenter multinational studies evaluating initial therapy and intensified therapies are required to determine efficacy and side effects of treatment. One approach would be to standardize treatment protocols across centers similar to the approach used in oncology. Alternatively, the heterogeneous treatment protocols across centers may be a method in capturing real world data, without indication bias, and answer important clinical questions as recently done comparing clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with MS. Repurposing of medications tested for other antibody mediated conditions with similar pathological mechanism may be explored while specific drugs are developed for MOGAD. Utilization of data from the randomized control trials for NMOSD and subanalysis of the treatment response in patients with MOG-Ab (some of them included in the seronegative NMOSD) would be a quick approach to evaluate the efficacy of anti-IL-6R and anti-CD19. However the number of patients are likely to be small and the trials were not primary power for these analyses. Preliminary results from phase II trial of Rozanolixizumab (anti-FcRn) demonstrating improvements in functional outcome measures in patients with myasthenia gravis and acetylcholine receptor antibodies may also prove beneficial in MOGAD as these two conditions share similarities in terms of immunopathology. Finally, in anticipating the launch of a randomized control trial in MOGAD, there is an urgent need to identify disease specific biomarkers of outcomes and treatment response.
MOGAD: review from the ECTRIMS workshop

**Acknowledgements**

The workshop was sponsored by ECTRIMS. We thank Ines Brunkow for technical assistance in preparing and organizing the workshop.

We dedicate this report to our dear colleague and friend Rogier Hintzen, who sadly passed away shortly after the workshop.
Financial disclosure statement

Dr. Marignier reports personal fees and non-financial support from Viela Bio, non-financial support from Merck, non-financial support from Biogen, personal fees and non-financial support from Roche, personal fees from UCB, outside the submitted work.

Dr. Hacohen has nothing to disclose.

Dr. Cobo-Calvo received funding from the Instituto de Salud Carlos III (Spain) JR19/00007.

Dr. Pröbstel reports grants from the Swiss National Science Foundation, the European Research Council, the National Multiple Sclerosis Society, the ProPatient Foundation, the Goldschmidt-Jacobson-Foundation and intramural Funding from the University of Basel and research support and personal fees (used for research) from Biogen.

Dr. Aktas reports grants from German Research Foundation (DFG), grants from German Ministry of Education and Research (BMBF), personal fees from Alexion, personal fees from Almirall, grants and personal fees from Biogen, personal fees from Merck, grants and personal fees from Novartis, grants and personal fees from Roche, personal fees from Sanofi, personal fees from Teva, personal fees from Viela Bio, outside the submitted work.

Dr. Alexopoulos has nothing to disclose.

Dr. Amato reports grants and personal fees from Merck, grants and personal fees from Biogen, grants and personal fees from Sanofi Genzyme, grants and personal fees from Teva, grants and personal fees from Roche, grants and personal fees from Novartis, outside the submitted work.

Dr. Asgari has nothing to disclose.

Dr. Banwell reports personal fees from Novartis, outside the submitted work.

Dr. Bennett reports personal fees from Roche, personal fees from Genentech, personal fees from Viela Bio, personal fees from Chugai Pharma, personal fees from Alexion, grants and personal fees from Novartis, personal fees from Genzyme, personal fees from Teva Neuroscience, grants and personal fees from EMD Serono, personal fees from Frequency Therapeutics, personal fees from Equillum, personal fees from Clene Nanoscience, personal fees from Mitsubishi-Tanabe, personal fees from Reistone Bio, grants from National Institutes of Health, grants from Guthy Jackson Charitable Foundation, grants from National Multiple Sclerosis Foundation, outside the submitted work; In addition, Dr. Bennett has a patent Aquaporumab issued.

Dr. Brilot reports grants from National Health Research Medical Council (NHRMC, Australia), grants from University of Sydney Research Excellence Initiative, personal fees from Biogen, personal fees from Merck, outside the submitted work; and F. Brilot discloses the use of live CBA in her laboratory.

Dr. Capobianco reports personal fees from Biogen, personal fees and non-financial support from Merck, personal fees and non-financial support from Sanofi, personal fees from Novartis, personal fees and non-financial support from Roche, outside the submitted work.

Dr. Chitnis reports consulting fees from Biogen Idec, Novartis, Sanofi, Bayer, Celgene, Genentech; grants from Novartis, Octave Bioscience, EMD Serono, Verily Life Sciences; all outside the submitted work.

Dr. Ciccarelli reports grants from Spinal Cord Research Foundation, grants from Rosetrees Trust, personal fees from Novartis, personal fees from Neurology, grants from Progressive MS Alliance, grants from Bioclinica & GE Neuro, grants from EU-H2020, grants from UK MS Society, grants from National MS Society, grants and other from NIHR UCLH BRC, grants
MOGAD: review from the ECTRIMS workshop

and other from NIHR Research Professorship, outside the submitted work; Dr. Ciccarelli reports grants from MS Society of Great Britain & Northern Ireland, grants from NIHR UCLH BRC, grants from National MS Society, during the conduct of the study; grants from Spinal Cord Research Foundation, grants from Rosetrees Trust, personal fees from Novartis, personal fees from Teva, personal fees from Roche, personal fees from Neurology, personal fees from Multiple Sclerosis Journal, grants from Progressive MS Alliance, grants from Bioclinica & GE Neuro, grants from EU-H2020, personal fees from Merck, outside the submitted work; Dr. Ciccarelli reports grants from Spinal Cord Research Foundation, grants from Rosetrees Trust, personal fees from Novartis, personal fees from Neurology, grants from Progressive MS Alliance, grants from Bioclinica & GE Neuro, grants from EU-H2020, grants from UK MS Society, grants from National MS Society, grants and other from NIHR UCLH BRC, grants and other from NIHR Research Professorship, grants from MRC, outside the submitted work; Dr. Deiva reports personal fees and non-financial support from Novartis, personal fees from Biogen, personal fees from Merck, from Roche, outside the submitted work

Jérôme De Sèze has nothing to disclose

Dr Fujihara reports personal fees from UCB, grants from Ministry of Education, Science and Technology of Japan, grants from Ministry of Health, Welfare and Labor of Japan, during the conduct of the study; personal fees from Chugai/Roche, personal fees from Alexion, personal fees from Viela Bio, personal fees from AsahiKasei Medical, personal fees from Mitsubishi Tanabe, personal fees from Biogen/Eisai, personal fees from Novartis, personal fees from Teijin, personal fees from Bayer, personal fees from Ono, personal fees from Nihon Pharmaceutical, personal fees from Takeda, outside the submitted work

Dr Jacob has nothing to disclose

Dr Kim reports grants from National Research Foundation of Korea, personal fees from Alexion, grants and personal fees from Aprilbio, personal fees from Celltrion, personal fees from Eisai, personal fees from HanAll BioPharma, personal fees from Merck Serono, personal fees from Norvatis, personal fees from Sanofi Genzyme, personal fees from Teva-Handok, personal fees and other from Viela Bio, other from Multiple Sclerosis Journal, other from Journal of Clinical Neurology, outside the submitted work

Dr Kleiter reports personal fees from Biogen, personal fees from Novartis, personal fees from Merck, personal fees from Sanofi Genzyme, personal fees from Roche, personal fees from Mylan, personal fees from Alexion, personal fees from Celgene, grants and personal fees from Chugai, personal fees from IQVIA, outside the submitted work

Hans Lassmann reports personal fees from Biogen, personal fees from Merck, personal fees from Roche, personal fees from Novartis, personal fees from Sanofi Aventis, personal fees from Medday, outside the submitted work;

Dr Leite is funded by NHS National Specialised Commissioning Group for Neuromyelitis optica, UK and by the NIHR Oxford Biomedical Research Centre, UK. She has been awarded research grants from The Myaware and University of Oxford. She has received speaker honoraria or travel grants from Biogen Idec, Novartis, and the Guthy-Jackson Charitable Foundation. Dr Leite serves on scientific or educational advisory boards for UCB, Argenx and Viela Bio.

Dr Lintington has nothing to disclose
Dr Meinl reports personal fees from Roche, personal fees from Novartis, personal fees from Sanofi, personal fees from Bioeq, personal fees from Merck, personal fees from Biogen, grants from Sanofi, grants from Merck, grants from Novartis, outside the submitted work.

Jacqueline Palace reports grants and personal fees from Merck Serono, personal fees from Teva, grants and personal fees from Chugai, grants and personal fees from MedImmune, grants and personal fees from Alexion, personal fees from Novartis, personal fees from Roche, grants and personal fees from ABIDE, personal fees from MEDDAY, personal fees from ARGEX, personal fees from Mitsubishi, personal fees from UCB, personal fees from Viela Bio, outside the submitted work; In addition, Dr. Palace has a patent Isis: Diagnosing Multiple Sclerosis issued, and a patent Know-how from the Numares Collaboration pending.

Dr Paul receives honoraria for lecturing, and travel expenses for attending meetings from Guthy Jackson Foundation, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Alexion, Roche, Parexel and Almirall.

Dr Petzold reports personal fees from Novartis, grants from Novartis, personal fees from Heidelberg Engeneering, personal fees from Zeiss, outside the submitted work; and Dr Petzold is part of the steering committee of the OCTiMS study which is sponsored by Novartis and the ANGI network which is sponsored by ZEISS. He has not received honoraria for these activities.

AP is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital National Health Service (NHS) Foundation Trust and University College London Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Dr Pittock reports grants from Grifols, other from Euroimmun, grants from NIH, grants, personal fees and non-financial support from Guthy Jackson Charitable Foundation, grants from AEA (Autoimmune Encephalitis Alliance), grants, personal fees, non-financial support and other from MedImmune, Inc., other from Astellas, personal fees from UCB, Inc., personal fees from Hoffman/LaRoche AG, grants, personal fees, non-financial support and other from Alexion Pharmaceuticals, Inc., outside the submitted work; In addition, Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued, a patent GFAP-IgG pending, a patent Septin-5-IgG pending, a patent MAP1B-IgG pending, a patent Kelch-like protein 11 pending, and a patent PDE10A pending.

Dr Reindl reports grants from Euroimmun, grants from Roche, during the conduct of the study; and The University Hospital and Medical University of Innsbruck (Austria; employer of Dr. Reindl) receives payments for antibody assays (MOG, AQP4, and other autoantibodies).

Dr Sato reports grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) - Brazil, grants from Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) - Brazil, grants and personal fees from TEVA, grants and personal fees from Merck, personal fees from Biogen, personal fees from Roche, personal fees from Viela Bio, outside the submitted work.
MOGAD: review from the ECTRIMS workshop

Dr Selmaj reports personal fees from Biogen, personal fees from Novartis, grants and personal fees from Merck, grants and personal fees from Roche, personal fees from Celgene, personal fees from TG Therapeutics, outside the submitted work

Dr Siva reports personal fees and non-financial support from F. Hoffmann-La Roche Ltd, personal fees and non-financial support from Sanofi-Genzyme, personal fees from Novartis, personal fees from Merck-Serono, personal fees from Teva, personal fees from Biogen Idec/Gen Pharma of Turkey, outside the submitted work

Dr Stankoff has received research grants from Sanofi-Genzyme, Roche, and Merck-Serono, and personal fees for lectures from Sanofi-Genzyme, Meck-Serono, Teva, Biogen and Novartis.

Dr Tintore reports personal fees from Almirall, personal fees from Bayer Schering Pharma, grants and personal fees from Biogen-Idec, grants and personal fees from Genzyme, personal fees from Merck-Serono, personal fees from Novartis, personal fees from Roche, personal fees from Sanofi-Aventis, personal fees from Viela Bio, personal fees from Teva Pharmaceuticals, outside the submitted work

Dr Traboulsee reports grants from Roche and personal fees from Roche, Sanofi Genzyme, Novartis, EMD Serono, Teva, and Biogen, outside the submitted work

Dr Waters reports personal fees from Alexion, personal fees from F. Hoffmann La-Roche, personal fees from BC Neuroimmunology, outside the submitted work; In addition, Dr. Waters has a patent Antibodies in Autoimmune Neurology with royalties paid.

Dr Waubant reports personal fees from DBV, Jazz Pharma, Emerald, outside the submitted work

Dr Weinshenker reports personal fees from RSR Ltd., personal fees from Oxford University, personal fees from Hospices Civil de Lyon, personal fees from MVZ Labor PD Dr. Volkmann und Kollegen GbR, personal fees from Viela Bio, personal fees from Alexion, personal fees from Roche Group (includes Genentech and Chugai), personal fees from Mitsubishi Tanabe, personal fees from Roivant, outside the submitted work; In addition, Dr. Weinshenker has a patent NMO-IgG (AQP4-IgG) for diagnosis of NMOSD with royalties paid.

Dr Derfuss reports other from Alexion, other from Actelion, grants and other from Novartis, other from Merck, grants and other from Biogen, other from Genzyme, other from GeNeuro, other from Mitsubishi Pharma, grants and other from Roche, other from Celgene, other from MedDay, outside the submitted work

Dr Vukusic reports grants, personal fees and non-financial support from Biogen, personal fees from Celgene, grants, personal fees and non-financial support from MedDay, grants, personal fees and non-financial support from Merck-Serono, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from Sanofi-Genzyme, personal fees from Teva, outside the submitted work

Dr Hemmer reports personal fees from Desitin, personal fees from Allergy Care, personal fees from TG Therapeutics, outside the submitted work

Author contributions

Romain Marignier - Study concept and design, acquisition of data, analysis and interpretation, writing
MOGAD: review from the ECTRIMS workshop

Yael Hacohen - Study concept and design, acquisition of data, analysis and interpretation, writing
Alvaro Cobo-Calvo - Study concept and design, acquisition of data, analysis and interpretation, writing
Anne-Katrin Pröbstel - Study concept and design, acquisition of data, analysis and interpretation, writing
Orhan Aktas - Acquisition of data, critical revision of the manuscript for important intellectual content
Harry Alexopoulos - Acquisition of data, critical revision of the manuscript for important intellectual content
Maria-Pia Amato - Acquisition of data, critical revision of the manuscript for important intellectual content
Nasrin Asgari - Acquisition of data, critical revision of the manuscript for important intellectual content
Brenda Banwell - Acquisition of data, critical revision of the manuscript for important intellectual content
Jeffrey Bennett - Acquisition of data, critical revision of the manuscript for important intellectual content
Fabienne Brilot - Acquisition of data, critical revision of the manuscript for important intellectual content
Marco Capobianco - Acquisition of data, critical revision of the manuscript for important intellectual content
Tanuja Chitnis - Acquisition of data, critical revision of the manuscript for important intellectual content
Olga Ciccarelli - Acquisition of data, critical revision of the manuscript for important intellectual content
Kumaran Deiva - Acquisition of data, critical revision of the manuscript for important intellectual content
Jérôme De Sèze - Acquisition of data, critical revision of the manuscript for important intellectual content
Kazuo Fujihara - Acquisition of data, critical revision of the manuscript for important intellectual content
Anu Jacob - Acquisition of data, critical revision of the manuscript for important intellectual content
Ho Jin Kim - Acquisition of data, critical revision of the manuscript for important intellectual content
Ingo Kleiter - Acquisition of data, critical revision of the manuscript for important intellectual content
Hans Lassmann - Acquisition of data, critical revision of the manuscript for important intellectual content
Maria-Isabel Leite - Acquisition of data, critical revision of the manuscript for important intellectual content
Christopher Linington - Acquisition of data, critical revision of the manuscript for important intellectual content
Edgar Meinl - Acquisition of data, critical revision of the manuscript for important intellectual content
Jacqueline Palace - Acquisition of data, critical revision of the manuscript for important intellectual content
Friedemann Paul - Acquisition of data, critical revision of the manuscript for important intellectual content
MOGAD: review from the ECTRIMS workshop

Axel Petzhold - Acquisition of data, critical revision of the manuscript for important intellectual content
Sean Pittock - Acquisition of data, critical revision of the manuscript for important intellectual content
Markus Reindl - Acquisition of data, critical revision of the manuscript for important intellectual content
Douglas Kazutoshi Sato - Acquisition of data, critical revision of the manuscript for important intellectual content
Krzysztof Selma - Acquisition of data, critical revision of the manuscript for important intellectual content
Aksel Siva - Acquisition of data, critical revision of the manuscript for important intellectual content
Bruno Stankoff - Acquisition of data, critical revision of the manuscript for important intellectual content
Mar Tintore - Acquisition of data, critical revision of the manuscript for important intellectual content
Anthony Traboulsee - Acquisition of data, critical revision of the manuscript for important intellectual content
Patrick Waters - Acquisition of data, critical revision of the manuscript for important intellectual content
Emmanuelle Waubant - Acquisition of data, critical revision of the manuscript for important intellectual content
Brian Weinshenker - Acquisition of data, critical revision of the manuscript for important intellectual content
Tobias Derfuss - Study concept and design, acquisition of data, analysis and interpretation, writing
Sandra Vukusic - Study concept and design, acquisition of data, analysis and interpretation, writing
Bernhard Hemmer - Study concept and design, acquisition of data, analysis and interpretation, writing

References


MOGAD: review from the ECTRIMS workshop


Table 1: Main clinical and paraclinical features in MOGAD

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Optic Neuritis</th>
<th>Transverse Myelitis</th>
<th>Acute Disseminated Encephalomyelitis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Up to 80% of patients, either at onset or during the disease course</td>
<td>Spinal cord involvement in 30% of episodes at onset and up to 50% during the disease course</td>
<td>Most frequent presentation in children 6-8</td>
</tr>
</tbody>
</table>
|                   | Simultaneous bilateral involvement in up to 40% | Motor disability may be similar to AQP4-Ab NMOSD | Only in 5% of adult presentation 2
|                   | Average high contrast VA at nadir counting figures,1,4 | Urinary, bowel and erectile dysfunction are common | Seizures at onset observed in up to 40% of children with ADEM 1,10 |
| Imaging           | Extensive T2 and gadolinium enhancing lesion in the optic nerve and/or chiasm, more evident on orbit MRI 11 | Initially described as LETM but short myelitis in up to 40%, 5,16 | Higher risk of post-ADEM epilepsy 8,10 |
|                   | Predominates in the anterior parts of the nerve but may extend to the optic chiasm 11 | Involvement of the corpus medullaris 6 | |
|                   | Perineural gadolinium enhancement 11 | Abnormalities confined to grey matter (sagittal line and axial H sign) and nerve roots 5 | |
|                   | OCT peripapillary RNFL thinning frequent but clinical-radiological paradox (despite severe atrophy of RNFL-VA is preserved) 13,14 | Less frequent gadolinium enhancement than AQP4-Ab NMOSD and MS 3 | |
|                   | Attack related RNFL thinning with temporal predominance 14 | Initial spinal cord MRI negative in 10% of patients. 17 | |
|                   | Microcystic macular in 24% 15 | Complete resolution at follow-up scan 5 | |
| CSF               | rare OCB (<10%) – frequent mild lymphocytic pleocytosis 1,2 | Good or full recovery from the onset attack in 60%, 16 | Large, hazy and poorly demarcated asymmetrical bilateral lesions, 7,18,19 |
|                   |                    | Younger patients were more likely to have a complete recovery from the onset attack. 4 | Deep grey matter involvement, most commonly affecting the thalamus. 20,21 |
| Risk of relapse and outcome | Patients <45 years at higher risk of relapse, compared to older ones 2 | Around 20% of patients reached a permanent motor disability at 2 years (DSS>3), 7 | Lesions may be highly enhancing 21 |
|                   | Reversible visual dysfunction was derived from the first episode in up to 75% 2 | In patients who reached DSS 3.0 and DSS 6.0, irreversible motor disability was explained by disability at onset attack in 68.4% and 67.5% of patients, respectively 1 | Corpus callosum, brainstem and cerebellum involved. 2 |
|                   | Progressive thinning of the pRNFL (but not of the combined ganglion cell and inner plexiform layer) may be observed in absence of new clinical attacks. 24 | Permanent bowel, bladder and erectile dysfunction are frequent despite good motor recovery 6 | Frequently associated to spinal cord involvement |
|                   |                    | Up to 50% of children will relapse following ADEM 1,2 | Complete resolution at follow-up scan 12,22 |

Abbreviations: ON: optic neuritis; TM: transverse myelitis; ADEM: acute disseminated encephalomyelitis; AQP4: aquaporin-4; MS: multiple sclerosis; RNFL: retinal nerve fiber layer; LETM: longitudinally extensive transverse myelitis; OCB: oligoclonal bands; VA: visual acuity; DSS: disability status scale; MDEM: multiple disseminated encephalomyelitis; NMOSD: neuromyelitis optica spectrum disorder

- Patients with MOGAD may have more uncommon phenotypes; 1) Isolated brainstem involvement in 7% and 30% of adult and children, respectively (postrema syndrome is rare).1,12,29 2) Cortical (unilateral or bilateral) encephalitis with or without white matter involvement.7,30–32 3) Cranial neuropathies or mixed central and peripheral syndromes; 33,34 4) Features of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS);35,36 5) Pseudotumor cerebri-like, associating bilateral papillitis to elevated cerebrospinal fluid opening pressure.37 For references see supplementary material pp 2-5.
### Table 2: Demographic, clinical and laboratory differences according to age at disease onset in MOGAD

<table>
<thead>
<tr>
<th>Age-groups(^{33, 38})</th>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; 10 years</td>
<td>10-17 years</td>
</tr>
<tr>
<td>Female:male ratio(^{33, 38})</td>
<td>Similar</td>
<td>Similar</td>
</tr>
<tr>
<td>Onset phenotype, %(^{8, 28, 36, 37})</td>
<td>(^{1})Optic neuritis 20-30</td>
<td>50-60</td>
</tr>
<tr>
<td></td>
<td>Brainstem &lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td></td>
<td>(^{4})ADEM 50-60</td>
<td>20-30</td>
</tr>
<tr>
<td>Patients relapsing at 2 years, %(^{8, 15, 33})</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(^{3})Risk of relapse(^{48})</td>
<td>very low</td>
<td>low</td>
</tr>
<tr>
<td>ARR, mean (SD)(^{38})</td>
<td>0.17 (0.31)</td>
<td>0.28 (0.38)</td>
</tr>
<tr>
<td>CSF-Oligoclonal bands, %(^{8, 34, 55})</td>
<td>&lt;5</td>
<td>&lt;12</td>
</tr>
<tr>
<td>(^{1})Motor disability, % (reaching EDSS 3.0)(^{33, 38})</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td>(^{1})VA disability, % (reaching VA 0.2)(^{38})</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Bladder/bowel/erectile dysfunction(^{33})</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Abbreviations: ADEM, acute disseminated encephalomyelitis; ARR, annualized relapse risk; SD, standard deviation; VA, visual acuity; ref cat, reference category; CSF, cerebrospinal fluid. Annualized relapse rates (ARRs) was calculated as number of relapses/year pre-treatment (excluding index event) and on-treatment only in patients with at least 6 months follow-up after initiation of treatment. Relapses were analysed for up to 2 years before initiation of therapy and for the duration of the time on therapy.

\(^{1}\)Patients aged <5 years-old initiated with ON in 10.5% and with ADEM phenotype in 68% of cases.

\(^{3}\)Age group <10 years-old is the reference category. Very low: lower risk than the reference category; low risk: 0-30% higher risk than the reference category; moderate risk: 30-60% higher risk than the reference category
MOGAD: review from the ECTRIMS workshop

Reported motor and visual acuity disability are based on cohort of patients with a median follow-up between 2 and 4 years. No data as evalable on the risk of relapse and Bladder/bowel/erectile dysfunction stratified to the different age group. We have therefor included a reference for all children and all adults. Refrain from drawing definitive conclusions regarding visual acuity disability and bladder/bowel and erectile dysfunction in children due to probable recall bias.
MOGAD: review from the ECTRIMS workshop

PANEL : Proposed Immunopathology of MOGAD

- Human MOG-Ab are typically of the IgG1 isotype\textsuperscript{42}
- The hypothesis of their pathogenic potency was derived from a monoclonal mouse antibody against MOG (8-18C5), established several decades ago\textsuperscript{93}
- The transfer of this monoclonal Ab to rodents that already have complement-dependent EAE enhances demyelination\textsuperscript{94}.
- Studies looking at the effect of MOG-Ab both in vivo and in vitro reveal primary demyelination\textsuperscript{95} with loss of the microtubule cytoskeleton of oligodendrocytes, resulting in altered expression of axonal proteins\textsuperscript{96}.
- The presence of CD4+ T cells in lesions from MOGAD patients, and recent data from rat models, suggest that T cells are important in the pathogenesis of the disease\textsuperscript{10, 97}
- Recently, MOG-specific B cells were identified in the peripheral blood from patients with MOGAD\textsuperscript{98}

Figure 1: Proposed model for immunopathology of MOGAD and treatment strategies

1A: The trigger for MOG-Ab production is yet unknown, but the auto-immune induction is thought to occur outside the CNS, in the peripheral immune system. Although post-infection autoimmunity has been raised as a likely mechanism for trigger no disease-specific pathogens have been identified. A number of mechanisms for post-infectious auto-immunity have been discussed, either in isolation or in combination, including molecular mimicry, bystander activation, epitope spreading, B-cell receptor mediated co-capture of antigens and polyclonal activation of B cells.

1B: Apart from MOG-Ab and MOG-Ab specific producing cells (B cell\textsuperscript{98}, plasmablasts and plasma cells), antigen-specific T follicular helper (Tfh) cells are also probably involved. Indeed, as human MOG-Ab are mainly of IgG1 phenotype, Tfh are required for differentiating B cell into MOG-Ab-producing plasma cells.

1C. Then, B cell, plasma cell and auto-antibodies need to cross the blood brain barrier to interact with their autoantigen, and mediate their pathogenic effects. One can speculate that MOG-Ab may get into the CNS when the blood-brain barrier is damaged, or via endothelial FcR.

1D. Once into the CNS, MOG-specific antibodies presumably bind MOG expressed on myelin where they lead to myelin injury and subsequent demyelination\textsuperscript{56, 97}. In parallel, MOG-Ab and plasma cells may also enhance activation of cognate MOG-specific CD4+ T cells or MBP-specific T cells and macrophages (Mφ) in the CNS\textsuperscript{99} Indeed, there is an increase of pro-inflammatory cytokines such as IL-6, IL-17, G-CSF and TNFalpha as well as B cell cyto-
MOGAD: review from the ECTRIMS workshop

/chemokines (BAFF, APRIL, CXCL13 and CCL19) described in the CSF of MOGAD patients

MOGAD= Myelin oligodendrocyte-IgG1 associated disease; Tfh= T folliculat helper cell; FcR= FC receptor; Mϕ= macrophages; G-CSF= granulocyte colony stimulating factor, TNF= tumor necrosis factor; CSF= cerebrospinal fluid